Correlation between serum CEA level and metabolic volume as determined by FDG PET in postoperative patients with recurrent colorectal cancer

Annals of Nuclear Medicine

Volumn 19, Issue 2, 2005, Pages 123-129

  Choi, Mi Yeon ^a   Lee, Kwang Min ^b   Chung, June Key ^a   Lee, Dong Soo ^a   Jeong, Jae Min ^a   Park, Jae Gahb ^a   Kim, Jung Hoe ^b   Lee, Myung Chul ^a  

^a Seoul National University   (South Korea)

^b Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

Author keywords

Carcinoembryonic antigen; Colorectal cancer; FDG PET; Tumor volume

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; FLUORODEOXYGLUCOSE F 18; TUMOR MARKER;

ADULT; ARTICLE; CLINICAL ARTICLE; COLORECTAL CANCER; DOSE CALCULATION; FEMALE; HUMAN; MALE; MATHEMATICAL MODEL; METASTASIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECURRENT CANCER; REGRESSION ANALYSIS; STATISTICAL SIGNIFICANCE; TUMOR VOLUME; WHOLE BODY SCINTISCANNING;

EID: 19744364028     PISSN: 09147187     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03027391     Document Type: Article

References (34)

1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics. CA Cancer J Clin 1997; 47: 5-27.
2. Cohen AM, Minsky BD, Schilsky RL. Colon cancer. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Principles and practice of oncology, 4th ed. Philadelphia; Lippincott, 1993: 929-977.
3. Fletcher RH. Carcinoembryonic antigen. Ann Intern Med 1986; 104: 66-73.
4. Berman JM, Cheung R, Weinberg DS. Surveillance after colorectal cancer resection. Lancet 2000; 355: 395-399.
5. Arnoud JP, Koehl C, Adolff M. Carcinoembryonic antigen (CEA) in diagnosis and prognosis of colorectal carcinoma. Dis Colon Rectum 1980; 23: 141-144.
6. Pietra N, Sarli L, Costi R, Ouchemi C, Grattarola M, Peracchia A. Role of follow-up in management of local recurrence of colorectal cancer, a prospective randomized study. Dis Colon Rectum 1998; 41: 1127-1133.
7. Graham RA, Wang S, Catalano PJ, Haller DG. Post surgical surveillance of colon cancer: preliminary cost analysis of physician examination, CEA testing, chest X-ray and colonoscopy. Ann Surg 1998; 228: 59-63.
8. Harrison LE, Guillem JG, Paty P, Cohen AM. Preoperative Carcinoembryonic antigen predicts outcome in node negative colon cancer patients: a multivariate analysis of 572 patients. J Am Coll Surg 1997; 42: 921-929.
9. Moertel CG, O'Fallon JR, Go VLM, O'Connell MJ, Thynne GS. The preoperative carcinoembryonic antigen test in the diagnosis, staging and prognosis of colorectal cancer. Cancer 1986; 58: 603-610.
10. Goslin R, Steele G, Macintare J, Mayer R, Sugarbaker P, Cleghorn K, et al. The use of preoperative plasma CEA levels for the stratification of patients after curative resection of colorectal cancers. Ann Surg 1980; 192: 747-751.
11. Grem J. The prognostic importance of tumor markers in adenocarcinomas of the gastrointestinal tract. Curr Opin Oncol 1997; 9: 380-387.
12. Anonymous. Clinical practice guideline for the use of tumor markers in breast and colorectal cancer. J Clin Oncol 1996; 14: 2843-2877.
13. Zervos EE, Badgwell BD, Burak WE Jr, Arnold MW, Martin EW. Fluorodeoxyglucose positron emission tomography as an adjunct to carcinoembryonic antigen in the management of patients with presumed recurrent colorectal cancer and nondiagnostic radiologic workup. Surg 2001; 130: 636-644.
14. Huebner RH, Park KC, Shepherd JE, Schwimmer J, Czemin J, Phelps ME, et al. A meta-analysis of the literature for whole-body FDG-PET detection of recurrent colorectal cancer. J Nucl Med 2000; 41: 1177-1189.
15. 18F]fluorodeoxyglucose in management of recurrent colorectal cancer. Arch Surg 1999; 134: 503-511.
16. Delbeke D, Vitola JV, Sandler MP, Arildson RC, Powers TA, Wright JE Jr, et al. Staging recurrent metastatic colorectal carcinoma with PET. J Nucl Med 1997; 38: 1120-1196.
17. 18F] fluorodeoxyglucose in identifying operable colorectal cancer metastasis to the liver. Arch Surg 1996; 131: 703-707.
18. Schiepers C, Penninckx F, De Vadder N, Merckx E, Mortelmans L, Marchel G, et al. Contribution of PET in the diagnosis of recurrent colorectal cancer: comparison with conventional imaging. Eur J Surg Oncol 1995; 21: 517-522.
19. 18F]fluorodeoxyglucose in recurrent colorectal cancer. Br J Surg 1994; 81: 1666-1670.
20. Flamen P, Hoekstra OS, Homans F, Van Custem E, Maes A, Stroobants S, et al. Unexplained rising carcinoembryonic antigen (CEA) in the postoperative surveillance of colorectal cancer: the utility of positron emission tomography (PET). Eur J Cancer 2001; 37: 862-869.
21. Johnson CR, Khandelwal SR, Schmidt-Ullrich RK, Ravalese JR, Wazar DE. The influence of quantitative tumor volume measurements on local control in advanced head and neck cancer using concomitant boost accelerated superfractionated irradiation. Int J Radiat Oncol Bio Phys 1995; 32: 635-641.
22. Jessup JM. Tumor markers-prognostic and therapeutic implications for colorectal carcinoma. Surg Oncol 1998; 7: 139-151.
23. Ruo L, Gougoutas C, Paty PB, Guillem JG, Cohen AM, Wong WD. Elective bowel resection for incurable stage IV colorectal cancer: prognostic variables for asymptomatic patients. J Am Coll Surg 2003; 196: 722-728.
24. Gold P, Freedman SO. Demonstration of tumor-specific antigens in human colonic carcinoma by immunological tolerance and absorption techniques. J Exp Med 1965; 121: 439-462.
25. Chung JK, Jang JJ, Lee DS, Lee MC, Koh CS. Tumor concentration and distribution of carcinoembryonic antigen measured by in vitro quantitative autoradiography. J Nucl Med 1994; 35: 1499-1505.
26. Hopper KD, Kasakes CJ, Van Slyke MA, Schwartz TA, TenHave TR, Jozefiak JA. Analysis of interobserver and intraobserver variability in CT tumor measurements. Am J Roentgenol 1996; 167: 851-854.
27. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-214.
28. Higashi K, Clavo AC, Wahl RL. Does FDG uptake measure proliferative activity of human cancer cells? In vitro comparison with DNA flow cytometry and tritiated thymidine uptake. J Nucl Med 1993; 34: 414-419.
29. Zasadny KR, Kison PV, Francis IR, Wahl RL. FDG-PET determination of metabolically active tumor volume and comparison with CT. Clin Pos Img 1998; 1: 123-129.
30. 18F]2- fluoro2-deoxyglucose (FDG PET) modeled in metastatic renal cell cancer. Clin Pos Img 2000; 3: 57-65.
31. Kim EE, Wong FCL. Thoracic cancer. In: Clinical PET. Principle and application. Kim EE, Lee MC, Inoue T, Wong WH (eds). New York; Springer, 2004: 262-282.
32. Kang W, So Y, Jeong JM, Kwark C, Lee DS, Kang SM, et al. The usefulness of F-18 FDG whole body PET in the evaluation of postoperative recurrence of cancer. Korean J Nucl Med 1997; 31: 372-380.
33. Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T. Intratumoral distribution of fluorine-18 fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studies by microautoradiography. J Nucl Med 1992; 33: 1972-1980.
34. Klapdor R. Colorectal carcinoma. In: Klapdor R (ed). Tumor markers in clinical oncology. An overview. Hamburg; Sorin Biomedica, 1994: 97-114.